Methods and systems for protein extraction

By using a dynamic cross-flow filter and a high dilution factor in plasma precipitates, the problem of low immunoglobulin G yield in existing technologies has been solved, achieving efficient protein extraction and separation suitable for industrial-scale production.

CN112074528BActive Publication Date: 2024-11-19CSL BEHRING AG
View PDF 10 Cites 0 Cited by

Patent Information

Application Number
CN201980030037.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-05-17
Filing Date
2019-05-17
Publication Date
2024-11-19
Estimated Expiration
2039-05-17

AI Technical Summary

Technical Problem

Existing technologies for extracting immunoglobulin G from plasma suffer from low yields and insufficient purity, especially in industrial-scale production, where conventional methods result in high impurity content and protein loss.

Method used

A novel method and system are employed to achieve efficient protein extraction and separation by mixing precipitate with liquid in a first tank to form a suspension and then continuously filtering using dynamic cross-flow filter elements, including a rotating cross-flow filter and a ceramic membrane, combined with high dilution factors and turbulent mixing.

Benefits of technology

It achieves an immunoglobulin G recovery rate of at least 95%, significantly improving protein yield while reducing impurity content and production costs, making it suitable for large-scale industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN112074528B_ABST
    Figure CN112074528B_ABST
Patent Text Reader

Abstract

The present invention relates to methods and systems for extracting proteins, in particular immunoglobulins, from a precipitate containing proteins with high yield, which are derived from human or non-human sources, such as plasma.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to methods and systems for extracting proteins from precipitates, particularly recombinant and / or plasma-derived proteins, including immunoglobulins (Ig), such as immunoglobulin G (IgG). Background Art

[0002] The demand for purified proteins such as specific antibodies has increased significantly. Such purified proteins can be used for therapeutic and / or diagnostic purposes.

[0003] Human plasma has been used in industry for decades for the production of widely established and accepted plasma-protein products, such as human albumin (HSA), immunoglobulins (IgG), coagulation factor concentrates (coagulation factor VIII, coagulation factor IX, prothrombin complex, etc.) and inhibitors (antithrombin, C1-inhibitor, etc.). In the development of such plasma-derived drugs, plasma fractionation methods have been established, resulting in intermediate products enriched in certain protein fractions, which are then used as the starting composition of plasma-protein products. Typical methods are reviewed in, for example, "Molecular Biology of Human Proteins" (Schultze HE, Heremans J.F.; Volume I: Nature and Metabolism of Extracellular Proteins 1966, Elsevier Publishing Company; Pages 236-317), and simplified schematic diagrams of such methods are given. These types of separation techniques allow the production of several therapeutic plasma-protein products from the same plasma donor pool. This is economically advantageous compared to producing only one plasma-protein product from a donor pool, and has therefore been used as an industrial standard in plasma fractionation.

[0004] In particular, cold ethanol fractionation of plasma was pioneered by EJ Cohn and his team during World War II, primarily for the purification of albumin (Cohn EJ, et al. 1946, J. Am. Chem. Soc. 62: 459-475). The Cohn fractionation method involves increasing the ethanol concentration from 0% to 40% in a stepwise manner while simultaneously reducing the pH from neutral (pH 7) to about 4.8, resulting in albumin precipitation. Although Cohn fractionation has been developed over the past 70 years, most commercial plasma fractionation methods are based on the original method or its variants (e.g., Kistler / Nitschmann), utilizing differences in pH, ionic strength, solvent polarity, and alcohol concentration to separate plasma into a series of major precipitated protein fractions (e.g., fractions I to V in Cohn).

[0005] Variants of Cohn fractionation have been developed with the goal of improving the recovery of multivalent IgG. For example, Oncley and co-workers used Cohn fraction II+III as starting material to produce active immunoglobulin serum fractions using a combination of cold ethanol, pH, temperature, and protein concentration different from those described by Cohn (Oncley et al., (1949) J. Am. Chem. Soc. 71, 541-550). Currently, the Oncley method is the classic method for producing multivalent IgG. However, it is known that by the fraction II+III step, about 5% of the γ-globulins (the antibody-enriched fraction) are co-precipitated with fraction I, and about 15% of the total γ-globulins present in the plasma are lost (see Table III, Cohn EJ, et al. 1946, J. Am. Chem. Soc. 62: 459-475). The Kistler / Nitschmann method aims to improve the recovery of IgG by reducing the ethanol content of certain precipitation steps (precipitation B compared to fraction III). However, the increased yield comes at the expense of purity (Kistler & Nitschmann, (1962) Vox Sang. 7, 414-424).

[0006] Initially, the immunoglobulin G (IgG) products derived from these fractionation methods were successfully used in the prevention and treatment of various infectious diseases. However, because the ethanol fractionation is a relatively rough process, the IgG product comprises impurities and aggregates, and its degree can only be administered intramuscularly. Since then, other improvements in purification process have caused the IgG products suitable for intravenous (called IVIg) and subcutaneous (called SCIg) administration.

[0007] It is estimated that in 2010, about 30 million liters of plasma were processed worldwide, providing a range of therapeutic products, including about 500 tons of albumin and 100 tons of IVIG. The IVIG market accounts for about 40-50% of the entire plasma fractionation market (P. Robert, Worldwide supply and demand of plasma and plasma derived medicines (2011) J. Blood and Cancer, 3, 111-120). Therefore, as the demand for IVIG remains strong (and the demand for SCIG increases), there is still a need to improve the recovery rate of immunoglobulins recovered from plasma and related parts. Preferably, this must be achieved in a way that ensures that the recovery rate of therapeutic proteins from other plasma sources is not adversely affected.

[0008] From a commercial perspective, the initial fractionation process is critical to the total production time and cost associated with the production of therapeutic proteins, particularly plasma-derived proteins, because subsequent purification steps will depend on the yield and purity of the protein of interest within these initial fractions. Although several variants of the cold ethanol fractionation process have been developed for plasma-derived proteins to increase protein yield at lower operating costs, higher protein yields are typically associated with lower purity. The present invention provides a method for fractionating a precipitate containing protein, particularly immunoglobulin G to achieve a higher yield. In a particular embodiment, an improved recovery in the protein of interest is achieved while minimizing impurity levels and / or losses in other therapeutic proteins.

[0009] One of the separation technologies widely used in the field of plasma fractionation / biotechnology is membrane filtration, which is a pressure-driven separation process to separate components based on their size and / or charge. There are two main membrane filtration methods, namely i) single-pass or direct flow filtration; and ii) cross-flow or tangential flow filtration.

[0010] Conventional tangential flow system is designed to control the fluid flow pattern of feed stream, so that the solute retained is left from the fixed film surface and returned to the transport of feed body. In this way, feed stream can be recirculated at a high speed at the vector tangent to the membrane plane to increase the mass transfer coefficient, allowing backward diffusion and cleaning the membrane surface to prevent clogging. In this type of filtering process, a pressure difference is applied along the length of the membrane to make fluid and filterable solute flow filter. Solution can be repeatedly passed through the membrane, while continuously extracting the fluid of the filter into a separate unit. However, there is a limitation in the protein purification degree that can be achieved, mainly due to the relatively wide phenomenon of the pore size distribution of concentration polarization, scaling and most of the membranes. Therefore, it is generally impractical to know that the macromolecular fractionation separation ability of ultrafiltration membrane is effectively used for large-scale separation of macromolecular mixtures such as plasma proteins.

[0011] US 2004 / 0167320 discloses a method and apparatus for separating molecules including immunoglobulins from complex mixtures such as milk (which typically contains 87% water and 13% solids) using conventional tangential flow filtration and microfiltration methods. The method includes clarification, concentration / filtration and sterile filtration steps, using three filtration unit operations. The clarification step removes larger particles from the product, while the concentration / filtration step removes most of the small molecules to increase purity and reduce the volume of the resulting product composition. The clarification and concentration / filtration steps are performed by pumping the feed cycle to concentrate the retentate or permeate. The first and second steps are sized and timed to be processed together, wherein the permeate from the second step is returned to the first step and mixed with the retentate of the first step. Once 95% of the product accumulates in the retentate of the ultrafiltration, clarification is stopped and concentration / diafiltration of the ultrafiltration material is started, wherein the product is concentrated and buffer is added to the ultrafiltration feed tank to flush out most of the small molecular weight proteins.

[0012] US 2011 / 0130545 A1 discloses a method for producing a secretory immunoglobulin A (S-IgA) composition from milk containing S-IgA using one or more microporous membrane filtration steps. The method comprises the steps of defatting, microfiltration and ultrafiltration by multiple diafiltration cycles, wherein the retentate of the microfiltration is combined with the diafiltrate. The combination of the retentate of the microfiltration and the diafiltrate is then subjected to subsequent microfiltration and concentration steps. The method used is continuous diafiltration. The disclosed method is based on membrane filtration technology, wherein the essential feature is the separation of particles suspended in a liquid feed stream on the basis of size.

[0013] EP1262225 discloses a continuous system for producing an emulsion using one or more membranes through which one liquid is continuously dispersed into another liquid to achieve a continuous phase.

[0014] There is a need for an improved method and system for the industrial-scale production of proteins, such as the production of immunoglobulins from precipitated materials containing immunoglobulins (e.g., derived from plasma or serum), which must meet strict safety standards. Currently used downstream technologies are relatively expensive, and their yields are not optimal. In addition, conventional filtration systems with fixed membranes have a tendency to scale rapidly in the presence of solutions containing resuspended protein precipitates; these are some of the problems that must be overcome. Therefore, there is an urgent need to develop more efficient, economical and faster methods for extracting and purifying proteins such as immunoglobulins from suspensions containing proteins. Summary of the invention

[0015] The inventors of the present invention have found an effective solution to the above mentioned problems by introducing a new method and a new system, in particular the first processing unit claimed in the present invention. The method of the present invention provides a cost effective, efficient and reliable solution to the existing problems.

[0016] According to a first aspect of the present invention, there is provided a method for extracting a protein of interest from a precipitate, the method comprising:

[0017] a. mixing the precipitate with a liquid in a first tank to form a suspension having a first dilution factor;

[0018] b. feeding the suspension to a first filtration unit comprising a dynamic filter element adapted to produce a first retentate and a first permeate enriched with a protein of interest;

[0019] c. diluting the suspension in the first tank to a second dilution factor by adding liquid, optionally by diluting the first retentate flow into the first tank; and

[0020] d. Recovering the first permeate enriched in the protein of interest in a second tank.

[0021] Protein precipitation is widely used in the downstream processing of bioproducts to concentrate proteins and purify them from various pollutants. The fundamental mechanism of precipitation is to change the solvation potential of the solvent, more specifically, by adding reagents and / or adjusting conditions (such as pH or conductivity) to reduce the solubility of the solute (i.e., protein). The subsequent precipitate is an insoluble solid comprising the protein of interest. It is generally in the form of a pellet or paste. Sometimes the precipitate can occur as a suspension. The solid portion can then be collected by, for example, filtering and / or centrifugation. Or such a suspension can be directly added to the first tank to form a first dilution factor. Another option is to add the suspension to the first tank, and then add the liquid to the first tank to form a first dilution factor. Therefore, in a specific embodiment, the precipitate comprising the protein of interest is in the form of a suspension when added to the first tank.

[0022] This method is particularly suitable for industrial scale production of the protein of interest. According to an embodiment of the first aspect of the present invention, the method of extracting the protein is an industrial scale method.

[0023] In another embodiment, the precipitate containing the protein of interest is an intermediate product of an alcohol fractionation process, preferably of plasma, more preferably of human plasma. In a preferred embodiment, the precipitate is obtained from a human plasma starting material. More preferably, the precipitate is obtained from 2500 L to 6000 L of human plasma starting material.

[0024] According to another embodiment of the first aspect of the present invention, the precipitate is a plasma fraction (intermediate). In a specific embodiment, the fraction is a Cohn fraction. In a preferred embodiment, the plasma fraction is selected from Cohn fraction I (FrI), Cohn fraction II+III (Fr II+III), Cohn fraction I+II+III (Fr I+II+III), Cohn fraction II (FrII), Cohn fraction III (Fr III), Cohn fraction IV (Fr IV), Cohn fraction V (Fr V), Kistler / Nitschmann precipitate A (KN A), Kistler / Nitschmann precipitate B (KN B), Kistler / Nitschmann precipitate C (KN C). In a particularly preferred embodiment, the plasma fraction is selected from Cohn fraction I (FrI), Cohn fraction II+III (Fr II+III), Cohn fraction I+II+III (Fr I+II+III) or Kistler / Nitschmann precipitate A (KN A). The plasma fraction can be a combination of different fractions. For example, the plasma fraction can be a combination of KNA and one or more of FrI, Fr II+III, and FrI+II+III. In another embodiment, the precipitate is an octanoic acid precipitate.

[0025] In another embodiment, the precipitate comprising the protein is obtained from a culture supernatant or a fermentation starting material. In some embodiments, the starting material is milk comprising the protein of interest. In other embodiments, the starting material is not milk.

[0026] According to another embodiment, the protein of interest is an immunoglobulin, preferably human immunoglobulin G (IgG), such as immunoglobulin G from human plasma or recombinantly produced immunoglobulin G.

[0027] According to another embodiment of the present invention, a suspension is prepared by mixing a precipitate comprising protein with a liquid such as a buffer or water, thereby providing a starting composition with a first dilution factor. When the precipitate comprising protein is almost solid (e.g., very thick paste, pellets, etc.), a liquid is added to the precipitate comprising protein so as to form a suspension as the starting composition.

[0028] The suspension with the first dilution factor of step a) is a mixture in which solute-like particles, sometimes referred to herein as solids, are present in the solution. The size of the particles can vary and include larger particles or include particles of smaller size that do not settle (i.e., in a colloidal form), wherein these larger particles would eventually settle if the solution were not mixed.

[0029] The first dilution factor can sometimes be referred to as the solid weight percentage (% w / v). This is defined as the weight of dry solids in a given volume of suspension divided by the total weight of the suspension of that volume, multiplied by 100. In particular embodiments, the weight percentage of the solid / suspension of step a) is at least 5% (i.e., a first dilution factor of about 1:20), or at least 7.5% or at least 10%, or at least 12.5%, or at least 15%, or at least 17.5%, or at least 20%, or at least 22.5%, or at least 25%, or at least 27.5%, or at least 30%, or at least 35%, or at least 40%, or at least 50%. In some embodiments, the weight percentage of the solid / suspension of step a) is 10%-30%. In some embodiments, the weight percentage of the solid / suspension of step a) is 15%-25%. In preferred embodiments, the weight percentage of the solid / suspension of step a) is 17.5%-22.5%. In a particular embodiment, the weight percent solids / suspension of step a) is 20%.

[0030] According to another embodiment of the present invention, the first dilution factor is at least 3 (1:3; number of precipitates: total amount), preferably 1-10, preferably 3-9, preferably 3-5, preferably about 3, 5, 6, 7, 9 or 10. For example, when the protein-containing precipitate is a pellet or a paste, in particular a very thick paste (with a very high viscosity), a liquid is required to suspend the paste or pellet.

[0031] For example, when the first dilution factor is 3 (1:3; 1 part protein-containing precipitate: total volume), this is equivalent to a dilution ratio of 1:2 (1 unit volume of solute (substance to be diluted) to 2 unit volumes of diluent to give a total volume of 3 total units).

[0032] In another embodiment, the first dilution factor (precipitate containing protein: total amount) in the first tank is at least 40, or at least 30, or at least 20, or at least 17.5, or at least 15, or at least 12.5, or at least 10, or at least 9, or at least 8, or at least 7, or at least 6, or at least 5.5, or at least 5, or at least 4.5, or at least 4, or at least 3.5, or at least 3, or at least 2.5, or at least 2, or at least 1.5, or at least 1.25. Preferably, the first dilution factor (precipitate containing protein: total amount) in the first tank is at least 4.

[0033] In some embodiments, the first dilution factor (precipitate containing protein: total amount) in the first tank is 1:1 to 1:20, or 1:2 to 1:20, or 1:3 to 1:20, or 1:4 to 1:20, or 1:5 to 1:20, or 1:6 to 1:20, or 1:7 to 1:20, or 1:8 to 1:20, or 1:10 to 1:20, or 1:1 to 1:15, or 1:2 to 1:15, or 1:3 to 1:15, or 1:4 to 1:15, or 1:5 to 1:15, or 1:6 to 1:15, or 1:7 to 1:15, or 1:8 to 1:15, or 1:10 to 1:15, or 1:1 to 1:15. :10, or 1:2 to 1:10, or 1:3 to 1:10, or 1:4 to 1:10, or 1:5 to 1:10, or 1:6 to 1:10, or 1:7-1:10, or 1:8 to 1:10, or 1:9-1:10, or 1:3-1:7, or 1:3-1:8, or 1:3-1:9, or 1:4-1:7, or 1:4-1:8, or 1:4-1:9, or 1:5-1:7, or 1:5-1:8, or 1:5-1:9, or 1:3.5 to 1:5, or 1:4 to 1:5, or 1:1 to 1:3, preferably 1:9, 1:7, 1:5 or more preferably 1:3 or 1:1.

[0034] Suitably, the protein concentration in the precipitate containing protein after resuspension is about 5-100g / L, preferably 10-50g / L, or more preferably 25-45g / L. This includes 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 and 100g / L and any range between these amounts. In other embodiments, the protein concentration can be about 5-20g / L, for example about 8-12g / L.

[0035] According to a preferred embodiment, the suspension in the first tank has a pH of about 3.0-9.0, preferably about 4.0-7.0, about 4.0-6.0, about 4.0-5.0, about 4.3-4.9, about 4.4-4.8, and more preferably about 5.0. Generally, the pH is measured in the solution before the protein precipitate is added to the solution; or the pH is measured immediately after the protein precipitate is mixed with the solution. Typically, the pH of the solution is measured after mixing the precursor components. Alternatively, the pH can be determined by calculation based on the expected amount and concentration of the components in the mixture.

[0036] According to an embodiment of the first aspect of the present invention, the suspension is continuously fed into the first filter unit. In a preferred embodiment, the suspension is continuously fed into the first filter unit until the suspension is diluted to at least a second dilution factor. In another embodiment of the present invention, the continuous separation process is a continuous filtration process, wherein one or more filter membranes or different types of filter membranes can be used. Continuous filtration processes such as dynamic cross-flow filtration can minimize the risk of filter component blockage.

[0037] Because the method of the first aspect of the invention comprises adding additional liquid to the suspension in the first tank, the second dilution factor is greater than the first dilution factor.

[0038] According to an embodiment of the first aspect of the present invention, the second dilution factor (volume of precipitate containing protein to volume of total recirculating liquid) is 6-70, 10-70, about 10, about 20, about 30, about 40, preferably about 20-50. In other embodiments, the second dilution factor is about 60 or about 70 (1:70; number of precipitates containing protein: total amount). In a specific embodiment, the second dilution factor is at least 20, or at least 30, or at least 40, or at least 50, or at least 60, or at least 70. The inventors of the present invention have found that such a high dilution factor can enhance the extraction efficiency, thereby improving the yield.

[0039] In another embodiment, the predetermined value of protein concentration in the suspension is 0.1 g / L or less, preferably about 0.001-0.1 g / L; typically about 0.05-0.1 g / L. Such a value is provided so that once such a threshold is reached, the separation process can be immediately terminated to avoid ineffective extraction and filtration processes. For example, when the total protein concentration in the suspension or solution is below 0.1 g / L, the total amount of IgG is estimated to be below about 40-50 mg / L, which makes it less economical to continue the continuous extraction and filtration of the product of interest.

[0040] According to an embodiment of the first aspect of the present invention, the dynamic filter element in the first filter unit is a dynamic cross-flow filter element. In a preferred embodiment, the dynamic cross-flow filter element is a rotating cross-flow filter element. More preferably, the rotating cross-flow filter element comprises a filter disc. The filter disc is usually mounted on a shaft member. In one embodiment, the rotating cross-flow filter element comprises at least one filter disc and at least one shaft member.

[0041] According to a preferred embodiment of the first aspect of the present invention, the filter disc membrane is a ceramic membrane. More preferably, the pore size of the ceramic membrane is in the range of greater than or equal to 50 nm to less than or equal to 100 nm. Such filter discs are provided by Kerafol and Flowserve.

[0042] The first filter unit in a preferred embodiment comprises a pressure vessel. The suspension from the first tank can be continuously fed into the pressure vessel through an inlet. A distribution manifold can be used to achieve uniform distribution of the suspension in the container. Therefore, in a specific embodiment, the pressure vessel comprises a distribution manifold. In some embodiments, the first filter unit comprises a rotating cross-flow filter element. Preferably, the filter element comprises more than one filter disc evenly spaced along at least one hollow central collection axis. The filter discs can be arranged horizontally or vertically. When in a horizontal direction, they are spaced apart along a hollow collection axis in a vertical direction. The collection axis and the disc are rotatable. The suspension in the pressure vessel can then penetrate the outer membrane of the rotating filter disc, thereby entering the hollow central portion of the disc, which is then guided to the central collection axis. Typically, the filtrate (i.e., the first permeate enriched with the protein of interest) can then be removed from the shaft portion of the first filter unit through a flange port. The remaining retentate in the pressure housing can be discharged from the container through an outlet at the same time. The retentate is usually recycled to the first tank to dilute the suspension. In this way, the retentate from the first filter unit can be used to dilute the suspension in the first tank to a second dilution factor.

[0043] Dynamic cross-flow filtration such as rotary filtration provides maximum filter efficiency. The cross-flow effect (tangential flow cleaning of the filter surface) is generated by rotating the filter discs, rather than by pumping excessive volumes over a fixed membrane as used in conventional (static) cross-flow filtration systems. The extreme cross-flow velocities generated on the rotating filter disc surface ensure highly efficient cleaning of the filter surface with very low energy consumption compared to conventional cross-flow technology.

[0044] Temperature affects the viscosity of the protein solution and also affects the flux when filtered with a membrane. The temperature of the starting suspension used in the method of the present invention should be in the range of 0°C to the temperature at which the relevant protein denatures. The temperature is suitably in the range of about 10°C to about 50°C. In a particular embodiment, the temperature is in the range of about 18°C ​​to about 35°C. According to a preferred embodiment, the temperature in the first processing unit is controlled, preferably 2-25°C, more preferably about 2-10°C. Such a temperature ensures optimal extraction and separation processes while maintaining the biological activity of the protein of interest throughout the process.

[0045] Filtration is performed at a transmembrane filtration pressure equal to or lower than the level that the membrane can withstand, depending on the material of the membrane used herein, for example, with a pressure of about 0.2 to about 3 bar. The transmembrane pressure is typically 0.1 to 2.5 bar, preferably 0.2 to 2.4 bar, more preferably 0.4 to 2.0 bar, 0.5 to 1.8 bar, 0.6 to 1.6 bar, 0.6 to 1.5 bar, 0.7 to 1.5 bar, and most preferably 0.8 to 1.5 bar. According to another embodiment, a pressure of up to 2 bar, preferably 0.1 to 2.0 bar, or about 1.5 bar, 1.0 bar or 0.5 bar is provided to the first processing unit.

[0046] According to another embodiment, the continuous extraction process is further assisted by adjusting the flow rate and / or residence time of the suspension or solution entering the first treatment unit and / or the flow rate of the first retentate / raffinate and / or the flow rate of the first permeate / extract. For example, in one embodiment, the linear velocity of the suspension or solution entering the pressure vessel (first treatment unit) can be about 0.27-1.66 m / s. In another example, the linear velocity of the first retentate can be 0.25-1.33 m / s. In another example, the linear velocity of the first permeate / extract can be 0.03-0.33 m / s. The linear velocity multiplied by the cross-sectional area gives the volume flow rate. In addition, due to the speed of the rotating filter disc, turbulence can be generated in the first treatment unit, wherein the velocity (sometimes referred to as the tangential velocity) can be about 1-7 m / s. According to one embodiment of the present invention, the speed of the rotating disc filter is 1-10 m / s. In a preferred embodiment of the present invention, the speed of the rotating disc filter is 5-7 m / s. More preferably, the speed of the rotating disc filter is 7 m / s at 60 Hertz (800 rpm). The rotating speed of the rotating cross filter element is about 600 rpm (50 Hz) - about 1600 rpm (100 Hz), preferably about 800 rpm (60 Hz) - about 1200 rpm (80 Hz), preferably about 800 rpm (60 Hz), about 1000 rpm (70 Hz) or about 1200 rpm (80 Hz). As used herein, the rotating speed in Hz refers to the speed of the motor. It can be associated with the speed in rpm using a suitable calibration curve.

[0047] This method can realize continuous extraction and separation process to recover the protein of interest from the initial precipitate / material to the greatest extent.Due to the extraction process, almost all the protein of interest is extracted from the precipitate containing protein and recovered in the subsequent stage.This method also allows liquid or diluent such as buffer or water to be recycled in a closed system, so the amount of liquid is kept in the whole process, and the occupation (i.e. large tank volume) can be reduced simultaneously.It is estimated that the method and system disclosed herein reclaims at least 95% or usually at least 98% of the protein of interest that originally existed in the precipitate containing protein.Therefore, in the specific embodiment of the first aspect of the present invention, the method provides the recovery rate of the protein of interest from the precipitate at least 95%, or at least 96%, or at least 97%, or at least 98% or at least 99%.In a preferred embodiment, the recovery rate is to reclaim at least 97% of the protein of interest from the precipitate.

[0048] The first permeate in the second tank may be subjected to a concentration step. According to a preferred embodiment of the first aspect of the present invention, the concentration process is an ultrafiltration performed in the second treatment unit.

[0049] According to a preferred embodiment of the first aspect of the present invention, the method additionally comprises subjecting the first permeate in the second tank to a continuous concentration process in a second filtration unit to produce a second retentate enriched in the protein of interest and a second permeate depleted in the protein of interest.

[0050] According to an embodiment of the first aspect of the present invention, the second filtration unit comprises a dynamic cross-flow filter element.

[0051] In a preferred embodiment of the present invention, dynamic cross-flow filter element or ultrafiltration filter device comprises the film with the molecular weight cutoff value less than the protein molecular weight being paid attention to.In these embodiments, select the membrane cutoff value so that the protein being paid attention to is retained in the second retention.As a general guide, it is possible to select the nominal membrane cutoff value to be less than the molecular weight of the protein being paid attention to one-third, to ensure that the protein is retained in the retention.In one embodiment, dynamic cross-flow filter element or static ultrafiltration filter element comprises the film with the molecular weight cutoff value greater than the protein molecular weight being paid attention to.In this class of embodiments, select the nominal membrane cutoff value to ensure that the protein being paid attention to passes through the membrane and is collected in the second permeate.

[0052] According to an embodiment of the first aspect of the invention, the method further comprises diluting the suspension in the first tank by continuously flowing a second permeate or a second retentate depleted of the protein of interest to the first tank, thereby facilitating dilution of the suspension to a second dilution factor.

[0053] According to an embodiment of the first aspect of the invention, the method further comprises diluting the suspension in the first tank by continuously flowing the retentate from the first filtration unit and the second permeate from the second filtration unit to the first tank, thereby diluting the suspension to a second dilution factor.

[0054] According to another preferred embodiment, a second tank is provided to receive the first permeate and / or the second retentate, wherein the flow rates of the first permeate and the second permeate are controlled so as to maintain a substantially constant product volume in the second tank. In a specific embodiment, in addition to the first permeate and / or the second retentate, fresh buffer is added to the first tank.

[0055] According to an embodiment of the first aspect of the invention, the first permeate / extract is collected in a holding tank (second tank), and once the suspension in the first tank is completely filtered / extracted, the first permeate / extract from the holding tank is subjected to a continuous concentration process. Such method steps are particularly suitable for processes of smaller industrial scales, where dead volumes in production equipment and pipelines can significantly affect the yield of the protein of interest. An example is a hyperimmune immunoglobulin product.

[0056] According to a preferred embodiment of the first aspect of the present invention, there is provided an industrial-scale method for extracting a protein of interest from a precipitate with high yield, the method comprising:

[0057] a. mixing the precipitate with a liquid in a first tank to form a suspension having a first dilution factor;

[0058] b. feeding the suspension into a first filtration unit, the first filtration unit comprising a rotating cross-flow filter element, the rotating cross-flow filter element comprising a filter disc having a ceramic membrane having an average pore size of 5 nm to 5000 nm, the filter element being suitable for producing a first retentate, and a first permeate enriched in the protein of interest;

[0059] c. diluting the suspension in the first tank to a second dilution factor by adding liquid, in part, by flowing the first retentate into the first tank;

[0060] d. recovering the first permeate enriched in the protein of interest in a second tank; and

[0061] e. subjecting the first permeate in the second tank to a continuous concentration process in a second filtration unit comprising a cross-flow filter element, thereby producing a second retentate enriched in the protein of interest and a second permeate depleted in the protein of interest;

[0062] f. optionally diluting the suspension in the first tank by continuously flowing the second permeate to the first tank, thereby diluting the suspension to a second dilution factor; and

[0063] g. Returning the second retentate enriched in the protein of interest to the second tank and / or collecting the second retentate enriched in the protein of interest.

[0064] According to a preferred embodiment of the present invention, the first retentate and the second permeate are continuously flowed into the first tank to dilute the suspension to a second dilution factor.

[0065] According to one embodiment of the present invention, the first filtration unit further comprises an adjustable scraping device adapted to control the bed height of the filter aid and / or the precipitated material on the outer surface of the ceramic filter disc membrane.

[0066] According to one embodiment of the invention, the first filtration unit comprises one or more hollow shafts suitable for collecting the first permeate, each shaft being connected to at least one filter disc comprising a ceramic membrane.

[0067] According to one embodiment of the present invention, the second filtration unit comprises a dynamic cross-flow filter element. In other embodiments, the second filtration unit comprises a static cross-flow filter element. In a preferred embodiment, the static cross-flow filter element is an ultrafiltration device comprising a membrane that retains the protein of interest in the second retentate.

[0068] According to one embodiment of the present invention, steps b) to c) or steps b) to f) are repeated until a second dilution factor or a predetermined value of protein concentration of the suspension or solution in the first tank is reached. This predetermined second dilution factor (sometimes referred to as the final dilution factor) ensures that the best yield can be harvested before continuing the extraction process becomes too uneconomical, which can also be determined using a predetermined value of protein concentration in tank 1. Protein concentration can be monitored in tank 1 by various methods known in the art, including UV absorbance, such as at 280 nm.

[0069] Optionally, a filter aid may be employed at an appropriate stage of the method. For example, a filter aid may be used in one or more steps involved in the preparation of the precipitate. Thus, in one embodiment, the precipitate comprises a filter aid. In one embodiment, the precipitate does not contain a filter aid. In this embodiment, a filter aid may not be used at all in the process (including any of the preceding processes), or, if present, the filter aid is removed before the suspension comprising the precipitate is fed to the first filtration unit, i.e. before step b). Preferably, the filter aid is removed before step b).

[0070] The method according to the first aspect of the invention is suitable for extracting a protein of interest from other solids comprising the protein. Examples include lyophilisates and crystalline solid forms comprising the protein of interest.

[0071] The product of the above method may then be further processed, including one or more of a chromatography step, a viral inactivation step, concentration, and formulation, such that the final product is suitable for administration to a subject, preferably a human subject.

[0072] According to a second aspect of the present invention, there is provided a closed system for extracting a protein of interest from a precipitate, the closed system comprising:

[0073] a. a first tank adapted to contain a precipitate in the form of a suspension having a first dilution factor;

[0074] b. a first filtration unit comprising a dynamic filter element connected to a first tank for receiving the suspension, the filter element being adapted to produce a first permeate enriched in the protein of interest and a first retentate depleted in the protein of interest, wherein the first filtration unit is adapted to return the first retentate to the first tank;

[0075] c. a second tank connected to the first filtration unit for recovering the first permeate enriched with the protein of interest;

[0076] d. A second filtration unit for concentrating the first permeate in the second tank, adapted to produce a second retentate enriched in the protein of interest and a second permeate depleted in the protein of interest, wherein the second unit is optionally adapted to return the second retentate to the second tank and / or return the second permeate to the first tank.

[0077] The closed system of the present invention reduces the cost of commodities such as water, buffers, and chemicals required to isolate the protein of interest and also reduces the space or footprint of the overall system compared to other commonly used systems while allowing for high yield recovery.

[0078] According to one embodiment of the second aspect of the present invention, the first filtration unit further comprises a scraping device, which is suitable for controlling the bed height of the filter aid and / or the precipitated material on the outer surface of the filter disc membrane. This device can also assist in controlling the filtration flow rate and / or preventing the filter from clogging. In some embodiments, the height of the scraping device relative to the distance from the filter disc membrane surface is adjustable. In a specific embodiment, the scraping device is positioned at least 20cm, or at least 15cm, or at least 10cm, or at least 9cm, or at least 8cm, or at least 7cm, or at least 6cm, or at least 5cm, or at least 4cm, or at least 3cm, or at least 2.5cm, or at least 2cm, or at least 1.5cm, or at least 1cm, or at least 0.5cm, or at least 0.25cm from the filter disc membrane.

[0079] According to another embodiment of the second aspect of the present invention, the second treatment unit comprises an ultrafiltration device.

[0080] According to another embodiment, the first filtration treatment unit is equipped with a rotating filter disc (dynamic filter element), and optionally a baffle for turbulent mixing of the contents of the first treatment unit, preferably with a tangential velocity of the disc of about 1-7 m / sec. Turbulence can be generated by the baffle, which can increase the extraction of the protein of interest, thereby achieving a high protein recovery.

[0081] According to another preferred embodiment, the first filter element comprises a filter membrane having a mean pore size of 5nm-5000nm, preferably 5nm-2000nm, 5nm-1000nm, 5nm-500nm, 5nm-200nm, 7nm-1000nm, more preferably 7nm-500nm, even more preferably 7nm-100nm, most preferably 7nm-80nm. Of course, the mean pore size can be in other combinations of the above-mentioned scope. Filter manufacturers usually assign terms such as nominal or mean pore size grades to commercial filters, which usually represent certain retention standards that meet particles or microorganisms rather than the geometric size of actual holes.

[0082] In a specific embodiment, the rotating cross-flow filter element comprises a filter disc. In some embodiments, the filter disc comprises a membrane having an average pore size of a microporous filter. In other embodiments, the filter disc comprises a membrane having an average pore size of an ultrafilter. In one embodiment, the average pore size of the filter disc membrane is in the range of greater than or equal to 5nm to less than or equal to 2μm. In a specific embodiment, the average pore size of the filter disc membrane is in the range of greater than or equal to 50nm to less than or equal to 0.5μm. In some embodiments, the filter disc membrane has an average pore size in the range of greater than or equal to 50nm to less than or equal to 100nm, or in the range of greater than or equal to 60nm to less than or equal to 90nm, or in the range of greater than or equal to 60nm to less than or equal to 80nm. In some embodiments, the filter disc membrane has an average pore size of 60nm or 80nm.

[0083] In a preferred embodiment, the rotary cross-flow filter element comprises a filter disc comprising a ceramic membrane.

[0084] The ceramic filter may for example contain Al2O3 or ZrO3, TiO2 or MgAl2O4. Ceramic disc filters are usually designed so that the filtrate is transported from the outside through the ceramic membrane to the hollow inner channels from which the filtrate can be collected.

[0085] Ceramic disc filters are available in a variety of sizes, including 374 mm (surface area 0.2 m 2 )、312mm(surface area 0.14m 2 ) and 152mm (surface area 360cm 2 ) in outer diameter. Typically, the thickness of a ceramic disc filter ranges from about 4.5 to 6 mm.

[0086] In an embodiment of the present invention, the ceramic filter disc comprises a membrane having an average pore size of a microporous filter. In other embodiments, the ceramic filter disc comprises a membrane having an average pore size of an ultrafilter. In certain embodiments, the average pore size of the ceramic membrane is in the range of greater than or equal to 5nm to less than or equal to 2μm. In a specific embodiment, the ceramic membrane has a pore size of about 0.2μm-2μm. In a specific embodiment, the ceramic membrane has a pore size of about 5nm-about 100nm. In other embodiments, the average pore size of the ceramic membrane is in the range of greater than or equal to 50nm to less than or equal to 0.2μm. In some embodiments, the average pore size of the ceramic filter membrane is in the range of greater than or equal to 50nm to less than or equal to 100nm, or in the range of greater than or equal to 60nm to less than or equal to 90nm. In a preferred embodiment, the average pore size of the ceramic filter membrane is in the range of greater than or equal to 60nm to less than or equal to 80nm. In another preferred embodiment, the ceramic membrane has an average pore size of 60nm. In another preferred embodiment, the ceramic membrane disc has an average pore size of 80nm.

[0087] According to another preferred embodiment, the second filter element comprises an ultrafiltration device comprising a membrane having an average molecular weight cut-off of 50 kD or less, preferably 30 kD or less, more preferably 10 kD or less or most preferably 5 kD or less.

[0088] In an embodiment of the present invention, the first treatment unit has a filtration capacity of at least 25 kg, or at least 50 kg, or at least 75 kg, or at least 100 kg, or at least 200 kg, or at least 300 kg, or at least 350 kg, or at least 400 kg, or at least 450 kg, or at least 500 kg, or at least 550 kg, or at least 600 kg, or at least 650 kg, or at least 700 kg, or at least 750 kg, or at least 1000 kg of starting sediment / m 2 Filter surface area. DETAILED DESCRIPTION

[0089] The present invention relates to a system and method for maximizing protein recovery and yield by utilizing a novel first processing unit or further using a second processing unit. A combination of extraction and separation methods is used in the present invention to process a precipitate containing solid protein, i.e., an intermediate material (e.g., a paste derived from a starting material), wherein the precipitate can be suspended in a liquid or diluent, such as water or a buffer, to form a suspension.

[0090] Typical protein-containing precipitates are formed during protein purification after exposure to a precipitant such as ethanol. The solid is commonly referred to as a precipitate or paste. The precipitate can be mixed with a liquid to form a suspension in which solid particles are distributed throughout the liquid. Under specific extraction conditions, the proteins contained in these particles can gradually dissolve into the liquid phase.

[0091] Because a large amount of water or buffer is required, the dissolution rate in the industrial-scale production process can cause problems. For the plasma fractionation process used to produce proteins such as albumin and immunoglobulin, this step can involve thousands of liters. Even if the tank can be used to accommodate such a large volume to achieve a large dissolution rate, due to the balance (Chatelier principle) between the protein dissolved in the solution and the protein retained in the precipitate or paste, the desired effect of higher yield cannot be achieved. This type of protein confined in the precipitate may not be recovered for further processing into the final product. This phenomenon is partly related to solubility equilibrium. When the compound in the solid phase is in chemical equilibrium with the compound dissolved in the solution, there is a known solubility equilibrium. This balance is an example of dynamic equilibrium, in which some individual molecules migrate between the solid phase and the liquid phase, so that the rate of dissolution and precipitation is equal to each other.

[0092] The present invention aims to solve the problem of recovering protein from a precipitate by continuously changing the solubility equilibrium. This is achieved by: 1) increasing the extraction efficiency through built-in components (utilizing a dynamic filtration system, which can be incorporated into a hollow spinning disk filter element) to allow repeated intimate phase contact; 2) continuously removing dissolved protein from the precipitate containing the protein (by applying the Le Chatelier principle - when any system in equilibrium undergoes a change in concentration (e.g. volume), temperature or pressure, the system will readjust to (partially) offset the effects of the imposed change and establish a new equilibrium. This means that by continuously increasing the volume at the resuspension point and continuously removing dissolved protein through a dynamic filter, the Le Chatelier principle can be used to ensure maximum protein transfer from the precipitate to the liquid phase. In some cases, the volume increase can be achieved by circulating the permeate in a continuous concentration step of the protein, thereby reducing buffer consumption.

[0093] With respect to the present invention, large-scale or industrial scale refers to a production process based on at least 200 L, preferably at least 500 L, and even more preferably at least 2000 L of starting material such as human plasma. For example, the typical commercial plasma donor pool size used in industrial-scale protein production is in the range of 2500 L-6000 L of plasma per batch. In a specific embodiment of the present invention, the precipitate is obtained from 2500 L-6000 L of plasma. Some commercial manufacturing processes can use larger plasma donor pool sizes, including up to 7500 L, up to 10000 L and / or up to 15000 L of plasma.

[0094] The methods and systems of the present invention can be used not only in large industrial scale applications, but also as stand-alone systems and / or methods for smaller production scale applications (where the starting material may be less than 200 L).

[0095] Many different methods can be used to selectively precipitate proteins from solutions, for example by adding salts, alcohols and / or polyethylene glycols in combination with pH adjustment and / or cooling steps. It is therefore expected that the present invention will be applicable to most protein precipitates, such as protein precipitates comprising immunoglobulin G, regardless of how they were initially prepared. It should be noted that the present invention can also be used to separate other types of proteins, including albumin, immunoglobulins (Ig), such as IgA, IgD, IgE or IgM, immunoglobulins of each type alone or their mixtures. It is foreseeable that recombinant proteins are also applicable in this regard.

[0096] For this reason, it should be noted that if the method is used to produce IgG, the precipitate containing protein can be any material (e.g., in the form of paste, precipitate, or inclusion body) containing IgG or be derived from starting material, such as a solution that can precipitate IgG by one or more of the above methods, whether from plasma or serum, fermentation broth, cell culture, protein suspension, milk or other original sources of human or animal origin. The material or solution containing immunoglobulin can contain monoclonal or polyclonal immunoglobulin. In some embodiments, the starting material containing immunoglobulin is a solution containing polyclonal antibodies. In other embodiments, the starting material contains monoclonal antibodies or fragments thereof. Therefore, within the knowledge of those skilled in the art, the term "immunoglobulin" as used herein can also be expressed as antibody, including natural or recombinant monoclonal antibodies or polyclonal antibodies.

[0097] For example, immunoglobulins (e.g., IgG) can be separated from human or animal blood, or produced by other means such as by recombinant DNA technology or hybridoma technology. In a preferred embodiment, immunoglobulins are obtained from plasma, usually from plasma pools derived from many donors. In order to obtain immunoglobulins from plasma, usually plasma is subjected to alcohol fractionation, which can be combined with other purification techniques such as chromatography, adsorption or precipitation. However, other methods can also be used. For example, the protein-containing precipitate can be a II+III precipitate according to the Cohn method, such as method 6, Cohnet.al.J.Am; Chem.Soc., 68(3), 459-475 (1946), method 9, Oncley et al.J.Am; Chem.Soc., 71, 541-550 (1946), or a I+II+III precipitate, method 10, Cohnet.al.J.Am; Chem.Soc., 72, 465-474 (1950); and the method of Deutschet.al.J.Biol.Chem.164, 109-118 (1946) or precipitate-A of Nitschmann and KistlerVox Sang.7, 414-424 (1962); Helv.Chim.Acta 37, 866-873 (1954). Alternative precipitates containing proteins of interest include, but are not limited to, other Oncley fractions, Cohn fractions, ammonium sulfate precipitates from plasma described by Schulze et al. in U.S. Pat. No. 3,301,842 containing immunoglobulin G. Other alternative precipitates containing proteins of interest include, but are not limited to, caprylic acid precipitates, such as described in EP893450.

[0098] "Normal plasma", "hyperimmune plasma" (such as hyperimmune anti-D, tetanus or hepatitis B plasma) or any plasma equivalent thereto can be used as the starting material in the cold ethanol fractionation process described herein.

[0099] The term "cryogenic supernatant" (also referred to as cryo-poor plasma, cryoprecipitate-depleted plasma, etc.) refers to plasma (derived from whole blood donation or plasma exchange) from which cryoprecipitate has been removed. Cryogenic precipitation is the first step in most plasma protein fractionation methods used today for large-scale production of plasma protein therapeutics. The method generally includes combining frozen plasma thawed under controlled conditions (e.g., at or below 6°C), and then collecting the precipitate by filtration or centrifugation. The supernatant portion is generally retained for use, which is referred to as "cryogenic supernatant" by those skilled in the art. The resulting cryogenic poor plasma has reduced levels of factor VIII (FVIII), von Willebrand factor (VWF), factor XIII (FXIII), fibronectin, and fibrinogen. Although the level of FVIII is greatly reduced, the level of fibrinogen can be as high as 70% of the original level. The cryosupernatant provides a common raw material for the manufacture of many therapeutic proteins, including α1-antitrypsin (AAT), apolipoprotein AI (APO), fibrinogen, antithrombin III (ATIII), prothrombin complex containing coagulation factors (II, VII, IX and X), albumin (ALB), and immunoglobulins such as immunoglobulin G (IgG).

[0100] The supernatant of 8% ethanol-precipitate (method of Cohn et al.; Schultze et al. (see above), page 251), precipitate II+III (method of Oncley et al.; Schultze et al. (see above), page 253) or precipitate B (method of Kistler and Nitschmann; Schultze et al. (see above Schultze), page 253) are examples of IgG sources that are compatible with industrial-scale plasma fractionation, alternatively, the starting material for the purification process to obtain IgG in high yield can be any other suitable material from different sources, such as fermentation and cell culture or other protein suspensions.

[0101] In the Cohn fractionation method, the first fractionation step results in part I, which mainly contains fibrinogen and fibronectin. The supernatant from this step is further processed to precipitate part II+III, then part III and II. Typically, part II+III contains about 60% IgG, together with impurities such as fibrinogen, IgM and IgA. Most of these impurities are then removed from part III, which is considered a waste part and is usually discarded. The supernatant is then processed to precipitate the main part containing IgG, part II, which can contain more than 90% IgG. The above % value refers to the % purity of IgG. Purity can be measured by any method known in the art, such as gel electrophoresis or immuno-turbidimetry. In the Kistler & Nitschmann method, part I is equivalent to part I of the Cohn method. The next precipitate / part is called precipitate A (part A). Although different, this precipitate is roughly equivalent to Cohn part II+III. The precipitate is then redissolved and the conditions are adjusted to precipitate precipitate B (part B), which is equivalent to Cohn part III. Again, this is considered a waste fraction and is typically discarded. The precipitate B supernatant is then further processed to produce precipitate II, which corresponds to the ℃ohn fraction II.

[0102] Specific protein-containing precipitates may contain plasma proteins selected from the group consisting of human and animal blood coagulation factors, including fibrinogen, prothrombin, thrombin, prothrombin complex, FX, FXa, FIX, FIXa, FVII, FVIIa, FXI, FXIa, FXII, FXIIa, FXIII and FXIIIa, von Willebrand factor, transport proteins including albumin, transferrin, ceruloplasmin, haptoglobin, hemoglobin and heme-binding protein, protease inhibitors including beta-antithrombin, alpha-antithrombin, alpha-2-macroglobulin, C1-inhibitor, tissue factor pathway inhibitor (TFPI), heparin cofactor II, protein C inhibitor (PAI-3), protein C and protein S, alpha-1 esterase inhibitor protein, alpha-1 antitrypsin, antiangiogenic (antiangionetic) proteins including potential antithrombin, highly glycosylated proteins including alpha-1-acid glycoprotein, antichymotrypsin, alpha-trypsin intergenic inhibitor, alpha-2-HS glycoprotein and C-reactive protein, and other proteins including histidine-rich glycoprotein, mannan-binding lectin, C4-binding protein, fibronectin, GC-globulin, plasminogen, blood factors such as erythropoietin, interferon, tumor factor, tPA, gamma CSF.

[0103] In a particular embodiment, the protein-containing precipitate is used to prepare therapeutic proteins derived from plasma, including immunoglobulins such as immunoglobulin G, albumin, fibrin, thrombin, prothrombin complex, fibrinogen, plasminogen, α1-antitrypsin, C1-inhibitor, apolipoprotein A1, α-acid glycoprotein, haptoglobin, hemoglobin, transferrin, and coagulation factors such as factor VII, factor VIII, and factor IX.

[0104] The concentration of protein in a sample (e.g., in a supernatant or its subsequently purified product) can be measured by any method known to those skilled in the art. Examples of suitable assays include high pressure liquid chromatography (HPLC; e.g., size exclusion HPLC), enzyme-linked immunosorbent assay (ELISA), and immunoturbidimetry. Such techniques can be used to evaluate the purity of a sample. In addition, gel electrophoresis such as SDS-PAGE with staining and optical density determination can be used to evaluate the purity of a sample and detect the presence of contaminating proteins. Reducing agents such as dithiothreitol can be used in SDS-PAGE to cut any disulfide-linked polymers.

[0105] The starting material comprising immunoglobulin G preferably has a total protein concentration of about 0.5-6.5% w / v, more preferably about 1.0-4.0% w / v, more preferably about 1.5-3.0% w / v, most preferably about 1.8-2.5% w / v, for example about 2.0% w / v.

[0106] In one embodiment, the liquid comprises a buffer comprising one or more of sodium acetate, phosphate and citric acid. In one embodiment, the phosphate is sodium phosphate, such as anhydrous sodium dihydrogen phosphate. Preferably, a buffer with a low conductivity is used, such as a buffer with a conductivity of less than 5 mS / cm, preferably less than 4 mS / cm, more preferably 0.01 mS / cm-4 mS / cm.

[0107] The method according to the invention allows to recover the protein of interest from a precipitate (e.g. paste) containing the protein with high yield. In the post-concentration stage, the recovery (ultrafiltration product) is typically at least 95% (w / w), preferably at least 96% (w / w), more preferably at least 97% (w / w), most preferably up to 98% (w / w), which is defined as the total amount of immunoglobulin G in the final filtered solution compared to the total amount of immunoglobulin G in the starting material.

[0108] The following is an example of calculation illustrating how the recovery of immunoglobulin G can be obtained according to the present invention. The first step involves determining the IgG content (total solubility) in the precipitate containing the protein, followed by a second step involving determining the IgG recovery using the continuous extraction method or system of the present invention.

[0109] As a first step, the protein-containing precipitate (about 50 g per experiment) is dissolved in a buffer (e.g., 0.12 M-0.25 M phosphate buffer, pH 7.6-8.0) to give a final dilution factor of 20 (1:20, or 1:19 final dilution ratio (by weight)). After resuspension for 2 h using an impeller mixer, the suspension is centrifuged at 4500G. This results in a first supernatant and a first precipitate. The volume of the supernatant can be determined by standard methods, and the IgG content of the supernatant can be determined, for example, by turbidimetry. The resulting precipitate is resuspended and treated again with the same buffer as described above to give a final dilution factor of 20 (1 part of the supernatant obtained: 19 parts of new buffer). The volume and IgG content of the resulting supernatant are determined again. This process is repeated, for example, 5 times, or as many times as necessary, so that the IgG content in the final supernatant is less than 10 mg / L (the limit of quantification is about 3.6 mg / L). This procedure ensures that the IgG content in the precipitate containing the protein is completely or optimally dissolved or extracted by buffer. Repeat this experiment several times (in this example, repeat 12 separate experiments). Repeat this process with the different starting precipitates produced by the fractionation of source plasma, giving similar reliable results. Table 1 below shows the content of total protein and IgG recovered from the precipitate containing the protein.

[0110] Table 1: Determination of IgG content (total solubility) in the protein-containing precipitate

[0111] Cumulative dilution factor (paste: buffer) Total protein recovered (g / kg paste) Recovered IgG (g / kg paste) Weight: Weight (min-max) (min-max) After 1 extraction 1∶20 131.8-158.9 68.7-72.8 After 2 extractions 1∶40 16.2-23.1 7.1-10.5 After 3 extractions 1∶60 3.5-7.4 0.6-1.8 After 4 extractions 1∶80 1.1-2.3 0.05-0.2 After 5 extractions 1∶100 0.2-0.4 0.01-0.03 Total extraction 152.8-192.1 76.5-85.3

[0112] In the second step, the same protein-containing precipitate is used for the experiment, using the continuous extraction and separation method or system according to the present invention. A total amount of 1 kg of the protein-containing precipitate (precipitate A) is dissolved in a buffer (e.g., 10 mM phosphate, 10 mM acetate & 2 mM citric acid) for 30 minutes to give a starting suspension, the first dilution ratio of which is 5 (1: 6 by weight; or a first dilution factor equal to 6 (1: 6)). The pH of the suspension is 4.6. The suspension is transferred from the first tank to the first filtration treatment unit for continuous extraction and separation process. The filtrate (first permeate) is collected in the second tank. For every 100-200 ml of collected filtrate, 100-200 ml of fresh buffer (or the recirculation buffer (i.e., the second permeate) after the UF step) is added to the first tank, so that the volume of the filtered suspension remains constant in the first tank. The filtration is terminated after 4 hours, so that the total protein concentration in the suspension is expected to be less than 0.1 g / L and / or the IgG concentration is less than 50 mg / L. Table 2 below shows the recovery rate of IgG.

[0113] Table 2: IgG recovery determined using the continuous extraction filtration system of the present invention

[0114] The starting precipitate used Sediment A Amount of initial precipitate (kg) 1.0 First dilution factor (paste: total amount (by weight)) 1∶6 Total protein (at the first dilution factor) (g / kg paste) 116.4 IgG amount (at the first dilution factor) (g / kg paste) 61.7 Final dilution factor (end of sequential extraction & filtration) 1∶31 Total protein (after reaching the final dilution factor) (g / kg paste) 168 IgG amount (after reaching the final dilution factor) (g / kg paste) 78.9 IgG amount (after ultrafiltration) (g / kg paste) 78.6

[0115] In this example, the experiment was performed offline using a continuous extraction filtration unit to show that the yield of total protein and IgG increased. "Offline" means that the buffer added is not obtained from the second filtration unit. The ultrafiltration in the second filtration unit is performed separately. Table 2 also shows that the IgG amount at the end of the final (second) dilution factor (1: 31 = 78.9 g / kg) is lower than that at the first dilution factor (1: 6 = 61.7 g / kg). This is due to the fact that not all IgG is extracted or dissolved in a buffer at one time, but is extracted or dissolved over a period of time or repeated dissolution procedures. Therefore, the IgG yield is improved by continuous extraction and filtration according to the present invention.

[0116] As shown in Tables 1 and 2 above, a yield of immunoglobulin G according to the present invention with a recovery rate of at least 95% was achieved. The recovery rate (of the continuous extraction and filtration according to the present invention) was calculated by multiplying the ratio of (total amount of IgG in the continuous filtrate: average amount of total dissolved IgG in Table 1) by 100.

[0117] Total IgG (after reaching final dilution factor) = 78.9 g / kg

[0118] Average total IgG extraction (Table 1) = (76.5 + 85.3) / 2 = 80.9 g / kg

[0119] IgG yield (recovery rate) = 78.9 / 80.9 x 100% = 97.53%

[0120] It is thus demonstrated that an IgG recovery of at least 95% or about 98% can be achieved according to the present invention.

[0121] High recovery at this early processing step (before further downstream processing steps) is a prerequisite for achieving higher yields in the final batch stage. The present invention utilizes an extraction process in which the protein-containing precipitate (e.g., paste) is actually suspended at a high dilution factor (e.g., 40-70; 1:40 and 1:70). For example, 1 kg of protein-containing precipitate (e.g., paste) is resuspended in 3 kg of liquid (e.g., buffer), resulting in a first dilution factor of 4 (1:4) for the starting suspension. Recirculation of 66 kg of buffer feed stream results in a final dilution factor of 70 (1:70). The extraction method used in the present invention allows higher amounts of immunoglobulin G to be released into the suspension / solution, thereby changing the equilibrium (as discussed below), allowing more efficient separation of immunoglobulin G from the suspension.

[0122] In a preferred embodiment, the crude protein precipitate containing immunoglobulin G (ie, the protein-containing precipitate) is suspended in a buffer to obtain a starting suspension. In some embodiments, the buffer may contain acetate or phosphate, or additional citric acid.

[0123] In a most preferred embodiment, the product of extraction and filtration of the immunoglobulin G enriched suspension or solution comprises human immunoglobulins, wherein at least 95% or up to 98% of the immunoglobulin G content is recovered from the starting precipitate, or after reaching the second dilution factor, an immunoglobulin G protein concentration of less than 0.1 mg / ml, preferably less than 0.05 mg / ml can be detected in the final suspension. The approximate distribution of immunoglobulin G subclasses is generally similar to the average subclass distribution in human plasma.

[0124] In addition, typically 1 kg of precipitate A (precipitate containing protein) contains about 170 g of total protein (range: 150-190 g protein / kg precipitate). The total protein is composed of about 50%-60% IgG (thus ranging from 75-95 g / kg precipitate). According to a method of the present invention, when a recovery rate of about 98% of IgG is achieved, this means that a total amount of 73.5-93.1 g / kg of IgG is obtained from the precipitate containing protein (precipitate A).

[0125] As will be described in detail in the examples below, due to the improved extraction process for extracting immunoglobulin G disclosed in the present method, wherein the improved method includes treating the paste (i.e., the precipitate / material containing the protein) with a larger volume of buffer, a surprisingly high recovery rate of about 98% can be obtained regardless of the pH of the buffer. Lower final dilution factors (e.g., from 5 to up to 14-15) are currently commonly used in the art. For example, in WO2016012803, the weight of the waste portion relative to the solvent is generally about 1:2 to about 1:10. Preferably, the weight of the solvent can be about 4 times the weight of the waste portion, i.e., the weight ratio of the waste portion to the solvent is about 1:4. Therefore, the present invention enables the recovery rate to be improved by providing a method for exposing the precipitate containing immunoglobulins to a higher volume (20, 30, 40 or higher high final dilution factors). Additional factors that also play a role include the introduction of turbulence in the suspension, pressures of up to 2 bar in the first and / or second processing units, and the closed filtration system according to the present invention has an improved extraction efficiency, resulting in a high recovery rate of immunoglobulin G extracted from the starting precipitate. Furthermore, in addition to the unexpectedly high recovery, the present invention provides other advantages, in particular scalability, allowing the process of the invention to be used in existing facilities due to the smaller footprint and lower costs associated with operating a lower total volume; moreover, it also allows the controllability of parameters that can affect the quality and stability of immunoglobulin G. Finally, the use of dynamic filtration enables efficient filtration of suspensions with high solids content.

[0126] In chemistry, for example in protein separation, Le Chatelier's principle or "law of equilibrium" can be used to predict the effects of changes in conditions on chemical equilibrium. When any system in equilibrium undergoes a change in concentration, temperature, volume or pressure, the system will readjust itself to (partially) offset the effects of the imposed changes and establish a new equilibrium. In other words, whenever a system in equilibrium is disturbed, the system will adjust itself in a way that negates the effects of the changes. For example, at equilibrium, the concentration of immunoglobulins in the suspension on both sides is constant. If a small amount of immunoglobulins is removed from the reaction at equilibrium, this will shift the equilibrium to the side with the reduced concentration change due to the change in the concentration of the immunoglobulins. According to Le Chatelier's principle, the system will try to partially resist the changes that affect the original equilibrium state. The reaction rate, the extent of the product and the yield will in turn change in accordance with the impact on the system.

[0127] If the system is in equilibrium and the concentration of one of the species involved in the reaction increases, the system readjusts to reduce the concentration of that species. Thus, the reaction proceeds in a way that consumes some of the increased concentration. Similarly, if the concentration of some species decreases, the reaction proceeds to compensate for the loss in concentration.

[0128] In other words, this results in an increase in the removal of immunoglobulins from one phase of the suspension, i.e., precipitation to the liquid phase, while immunoglobulins (e.g., IgG) are continuously removed from the system while the concentration of immunoglobulins in the suspension solvent is reduced by dilution. By repeating this process, substantially all of the immunoglobulins contained in the precipitate of the suspension can be extracted from the protein-containing precipitate, in particular with the high final dilution factor of at least 30 disclosed in the present invention, preferably, for example, 40 (1:40) or higher, and can be further assisted by using, for example, the suggested buffer composition, or additionally assisted by using a higher pH, to maximize the recovery of immunoglobulin G from the protein-containing precipitate. Compared to the prior art, the method and system of the present invention allow the recovery of substantially all of the immunoglobulin G from the protein-containing precipitate (e.g., paste or precipitate).

[0129] The ultrafiltration product can be further processed subsequently, such as chromatographic steps, virus inactivation steps, concentrated and prepared, so that the final product can be administered to, for example, the human body. The final product can be used to treat immune disease conditions, particularly autoimmune diseases and some nervous system diseases. These disease conditions include rheumatoid arthritis, systemic lupus erythematosus (SLE), antiphospholipid syndrome, immune thrombocytopenia (ITP), Kawasaki disease, Guillain-Barre syndrome (GBS), multiple sclerosis (MS), chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy (MMN), myasthenia gravis (MG), skin blistering disease, scleroderma, dermatomyositis, polymyositis, Alzheimer's disease, Parkinson's disease, Alzheimer's disease relevant to Down syndrome, cerebral amyloid angiopathy, Lewy body dementia, frontotemporal lobar degeneration or vascular dementia. In addition, final IVIG and SCIG products can be used for other medical procedures such as cell and organ transplantation.

[0130] To this end, it is reiterated that, due to its unique design, the first treatment unit according to the present invention provides a continuous extraction and separation process, in particular a filtration process. The first treatment unit can be equipped with a dynamic rotating filter element, for example comprising a ceramic-based membrane disc. Compared with conventional cross-flow technology, rotary filtration allows extreme cross-flow velocities (due to its efficient cleaning of the filter surface) and extremely low energy consumption. The cross-flow effect (tangential flow cleaning of the filter surface) is generated by the rotation of the filter disc rather than by large-scale suction. Ceramic filter discs have better resistance to chemical and thermal stress, high filtration flux and very long service life, and can be regenerated by backflushing or hot steam sterilization.

[0131] Rotating ceramic filter discs are usually assembled in a pressurized housing. The design of the discs shows drainage channels inside. The filtrate is transported from the outside of the disc to the inside. The rotation of the discs creates shear forces on the membrane surface. With this technology, the buildup of filter cake is avoided, resulting in high filtration flux. Some of the main parameters of rotary filtration are the rotation speed of the rotating ceramic filter discs and the solids content (concentration of the liquid due to the removal of the filtrate).

[0132] The term "precipitate containing a protein" refers to any material containing the protein of interest. In the context of immunoglobulins as the protein of interest, this term may refer to plasma, serum, precipitates prepared from plasma or serum, fermentation broth, inclusion bodies, cell culture supernatants, or precipitates prepared from such materials. Typically, in the context of the present invention, it refers to precipitates from plasma, such as Cohn or Oncley ethanol precipitates, or Kistler-Nitschmann precipitates.

[0133] The term "starting composition" refers to a suspension or solution prepared from a precipitate comprising a protein, typically prepared by diluting with water or a buffer according to a (first) dilution factor. In some cases, if dilution of the precipitate comprising a protein is not required, the precipitate comprising a protein may be the starting suspension.

[0134] "High yield" means that the yield of the protein of interest, such as immunoglobulin G (and other proteins and immunoglobulins), is at least 95%, preferably at least 96%, more preferably at least 98%, and most preferably above 98% of the amount of the protein of interest in the precipitate containing the protein.

[0135] The concentration of immunoglobulin in a sample (e.g., in a precipitate or a pharmaceutical grade purified product thereof) can be measured by any method known to those skilled in the art. It should be understood that the method used to measure immunoglobulin may depend on the nature of the sample. For example, it should be understood that when the sample is a precipitate containing immunoglobulins, it may be necessary to dissolve the precipitate (or a sample thereof) in a suitable buffer before measuring. Examples of suitable assays for measuring the protein of interest include high pressure liquid chromatography (HPLC; e.g., size exclusion HPLC), enzyme-linked immunosorbent assay (ELISA), and quantitative immunoturbidimetry.

[0136] "About" or "approximately" in connection with a given numerical value of a percentage, pH, amount or time or other reference means that the numerical value is included within 10% of the specified value.

[0137] Throughout the specification, unless the context requires otherwise, the word "comprise" or variations such as "comprises" or "comprising" will be understood to mean the inclusion of a stated element or integer or group of elements or integers but not the exclusion of any other element or integer or group of elements or integers.

[0138] Reference in this specification to any previous publication (or information derived therefrom) or any known matter is not, and should not be taken as, an acknowledgement or approval or any form of suggestion that the said previous publication (or information derived therefrom) or known matter forms part of the common general knowledge in the field to which this specification relates.

[0139] It must be noted that, when used in this specification, the singular forms "a", "an" and "the" include plural references unless the context clearly dictates otherwise. Thus, for example, reference to "a protein" includes a single protein, as well as two or more proteins.

[0140] Several preferred embodiments of the present invention will now be described in detail with reference to the accompanying drawings, wherein some of the lesser or non-critical features incorporated herein have been omitted for the sake of brevity. BRIEF DESCRIPTION OF THE DRAWINGS

[0141] The following drawings are not necessarily drawn to scale, but generally emphasis is placed on illustrating the principles of the various embodiments. In the following description, various embodiments of the present invention are described with reference to the following drawings:

[0142] Figure 1 A schematic flow chart overview of the system of the present invention is provided and described in more detail below.

[0143] Figure 2 Shown is the time flow rate through the first filtration unit in the presence (squares) and absence (circles) of filter aid.

[0144] Figure 1A schematic flow chart overview of a system 100 and a method according to a preferred embodiment of the present invention is described. A precipitate containing proteins, for example in the form of a suspension or in the form of a paste or precipitate, is suspended with a liquid such as a buffer. The composition and concentration of the buffer are in accordance with the above method so as to produce a starting composition such as a suspension having a first dilution factor of, for example, 3-10 (1:3 to 1:10). The suspension is placed in a first tank 1. The suspension can be fed to a first filtration unit 5 by a pump 2, and several types of pumps (e.g., piston pumps; rotary pumps; centrifugal pumps and membrane pumps) and a flow regulating valve 3 of a pipeline 12 can be used. The first filtration unit 5 is equipped with a rotating hollow shaft on which a filter disc is mounted (the filtrate flows from the outside of the hollow shaft to the inside). The first filtration unit 5 is further provided with a height-adjustable scraper to keep the thickness of the filter cake constant, thereby achieving a constant filtrate flow. The desired filtration pressure is controlled and adjusted by an overflow valve (unfiltered suspension outlet). The filter disc used can be a ceramic membrane, a depth filter (depth filtration) layer, and a sintered porous metal filter disc. Once the container of the first filtration unit 5 is full of suspension, continuous pressure extraction and separation can be started. The first filtration unit 5, which may include a pressure unit / container, has suitable internal settings and conditions to improve the extraction efficiency and the filtering process at the same time. The extraction efficiency is improved by turbulent mixing in the unit 5, and a mixer does not have to be used. However, it is foreseeable that an additional mixer can be provided to assist the extraction process by generating turbulence. In addition, a higher final dilution factor, such as 40 or 70 disclosed in the present invention, also improves the extraction efficiency, resulting in a high protein (e.g., IgG) yield. Of course, any other higher final dilution factor (higher than 70) can also be envisioned.

[0145] The filtrate flows through a flow meter 6 mounted on a pipe (or channel) 14 and is collected in a second tank 7. The unfiltered suspension flows back through a regulated outlet 3 mounted on a pipe 13 in the tank 1. When a defined volume in the second tank 7 is reached, the UF 8 concentration process can be started in the second filtration unit. The filtrate in the second tank 7 flows via a pipe 15 into an ultrafiltration (UF) system 8. The transmembrane pressure is set so that the permeate flow rate 17 is the same or almost the same as the first filtrate flow rate in the pipe 14. The permeate of the UF system 8 flows back to the first tank 1 via a pipe (or pipeline or channel) 17, while the retentate of the UF system (= concentrated protein) flows back to the second tank 7 via a pipe 16.

[0146] According to the present invention, the first treatment unit 5 is equipped with one or more rotating filter discs, which contain one or more first filter elements for turbulent mixing of the contents of the first treatment unit 5 to produce a first retentate and a first permeate. The first retentate can be fed back to the first tank 1 through a channel 13 via a control valve 3, while the first permeate can be fed to the second tank 7 through another channel 14. The first filter element can be a filter membrane based on a ceramic material with a pore size of about 5nm-5000nm, preferably 20nm-100nm or more preferably 30nm-80nm. It can also be foreseen that inorganic membranes or any other suitable membranes can also provide similar effects to ceramic-based membranes. The first filtration unit 5 can be equipped with a pressure control device 4 such as a pressure gauge to regulate the pressure therein. Similarly, a flow meter 6 can be installed in the system of the present invention for measuring the flow rate of a suspension or solution.

[0147] The feed stream from the second tank 7 can then be fed to the second filtration unit 8 through channel 15 for a second separation process. The second separation process can be a continuous concentration process (e.g., UF). The second filtration unit 8 is equipped with one or more second cross-flow filter elements, wherein the second cross-flow filter element can include an ultrafiltration membrane with an average molecular weight cut-off value of less than 50 kD. However, the membrane can also be less than 10 kD or more preferably less than 5 kD. The ultrafiltration membrane thus produces a second retentate, which is directed back to the second tank 7 through channel 16, while the second permeate is fed to the first tank 1 through channel 17. For this reason, it should be noted that the pressure of the second filtration unit 10 can be adjusted during the concentration step (ultrafiltration) so that the flow rates of channels 14 and 17 are substantially equal.

[0148] In the following description, a detailed description of the method according to the present invention is provided in several experimental examples.

[0149] Example

[0150] Example 1

[0151] According to the present invention, immunoglobulin G is extracted by a continuous extraction and separation process in the first processing unit.

[0152] An amount of 1 kg of the protein-containing precipitate (precipitate A) was dissolved in 10 mM sodium acetate, 10 mM phosphate and 2 mM citrate buffer for 30 minutes to obtain a first dilution factor of 10 (i.e. 1 kg of precipitate dissolved in 9 kg of buffer), wherein the pH of the suspension was about pH 4.6. The suspension was prepared in a first tank and fed to a first processing unit for a continuous extraction and separation process. The first processing unit was equipped with a rotary filter element comprising a ceramic-based membrane disc having a filter membrane with an average pore size of 80 nm. The ceramic filter used was a ceramic filter disc 152 having a diameter of Thickness d = 4.5 mm; and membrane surface area 360 cm 2 The tangential speed of the disk was about 7 m / s at 60 Hz (800 rpm). The average filtration rate was about 200 ml / min. During the continuous extraction and separation process, for every 200 ml of filtrate (first permeate) collected in the second tank, 200 ml of buffer were returned to the first tank from the second permeate obtained from the second filtration unit (ultrafiltration). After 4 hours, the filtration was stopped, with a predetermined protein concentration in the first tank of less than 0.1 g / L (equal to a final dilution factor of 31). A total amount of 3 kg of filtrate was further concentrated in the second filtration unit (10 kD ultrafiltration membrane) to 20 g / L.

[0153] A comparative experiment was performed using depth flow filtration according to the method of the prior art. The same batch of precipitate A was used in this experiment, wherein the precipitate was suspended in 0.22M sodium acetate buffer. A final dilution factor of 6 (i.e. 1 kg of precipitate dissolved in 5 kg of buffer) was used for this experiment. The suspension was mixed for 4 hours before depth filtration. Finally, the filtrate was concentrated to 20 g / L using an ultrafiltration membrane with an average molecular weight cutoff of 10 kD.

[0154] The results of immunoglobulin G yield are shown in Table 3. The IgG yield obtained using the continuous extraction method is higher than that of the prior art method. As explained above, the extraction method ensures that the precipitate is exposed to an increased volume of liquid (or final dilution factor). It is believed that this changes the dissolution equilibrium, which is conducive to increasing the extraction of immunoglobulin G from the precipitate material, which can then be recovered in the first permeate of the first filtration unit. As shown in Table 3, the dynamic filtration system of the present invention can increase the IgG yield by about 0.68g / L plasma equivalent (PEQ) compared to the prior art method. This is equivalent to about 10% of IgG in each liter of pooled plasma.

[0155] Table 3: Comparison of IgG yields between existing and new processes at different processing steps. (PEQ stands for plasma equivalent, i.e. the amount of IgG from each liter of plasma)

[0156]

[0157] Example 2

[0158] In this example, similar methods and equipment as described in Example 1 were used to compare IgG yields resulting from the use of different buffer compositions and different final dilution factors.

[0159] As shown in Table 4, a final dilution factor of 6 is applied to the control (sample A). This final dilution factor represents a commonly used final dilution factor widely practiced in the art. For example, WO2016012803 (page 15, line 30) recommends dilution by a factor of about 1:2 to about 1:10. In contrast, the present invention provides a practical means for allowing the use of a higher dilution ratio. In this embodiment, a final dilution factor of 40 is used for samples B and C.

[0160] The buffer in sample A contained 0.22 M sodium acetate. The buffer in sample B contained 5 mM acetate and 5 mM phosphate, while the buffer in sample C contained 10 mM acetate and 10 mM phosphate. Samples B and C both additionally contained 2 mM citric acid to maintain a constant pH after resuspension of the precipitate containing the protein. The pH of the starting composition in the form of a suspension of all samples was about 4.8.

[0161] The final dilution factor of sample A was 6, which was obtained by first dissolving about 1 kg of precipitate I+II+III in the above buffer (0.22 M acetate; one part precipitate and 5 parts buffer; 1:6 wt / wt; precipitate: total) according to the Cohn method10. The suspension was mixed for 4 hours at ambient room temperature. Afterwards, the suspension was filtered through a depth filter (0.2-0.45 μm, polypropylene) and finally passed through a 10 kD membrane Ultrafiltration was performed and concentrated to 20 g protein / L.

[0162] For sample B and for sample C, a total amount of 1 kg of protein-containing precipitate was dissolved in the above-mentioned buffer for 30 min to obtain a first dilution factor of 6, wherein the pH of the suspension was adjusted to about 4.6. The suspension was prepared in the first tank and fed to the first treatment unit for a continuous extraction process. In the continuous extraction process, for every 100-200 ml of filtrate collected in the second tank, 100-200 ml of buffer was returned to the first tank from the second permeate of the second treatment unit (ultrafiltration). When the total dilution factor was about 40, the filtering process was stopped. The filtrate was further concentrated to 20 g / L in the second filtration unit using an ultrafiltration membrane with a mean molecular weight cutoff of 10 kD.

[0163] Six different batches were used for the experiment (same batches were compared with each test buffer). The protein and IgG yields were then compared. The yield results showed that samples B and C increased 0.56 g IgG per L PEQ (average) compared to sample A (see Table 4).

[0164] Table 4: Comparison between the prior art method (control) and the method used in the present invention after the ultrafiltration concentration step

[0165]

[0166] Example 3

[0167] In this example, the effect of different pH on the yield of immunoglobulins G, M and A and other impurities using the continuous extraction system of the present invention is demonstrated. Two experiments were performed in which the IgG recovery was compared using citrate buffer and phosphate buffer. The protein-containing precipitate used in this example was 1 kg of precipitate I+II+III, which was derived from plasma treated with ethanol according to the Cohn method 10 or according to the method of Kistler and Nitschmann (1962, Vox Sang. 7, 414).

[0168] The lower pH sample was obtained by resuspending the above pellet in a citric acid buffer (sodium citrate-citric acid) to give a first dilution factor of 5 (1:5) at a pH of 3.5-3.9. The suspension was stirred at 20°C for 30 minutes.

[0169] The suspension is then transferred to the first tank, which is subsequently fed to the first filtration treatment unit for the continuous extraction and separation process as described in Example 1. The first treatment unit is started immediately after the system is filled with the suspension. The first permeate / extract is prepared from the first treatment unit, wherein the first permeate / first extract is collected in the second tank before the ultrafiltration concentration step (second filtration unit). The second permeate obtained from the ultrafiltration concentration step, which consumes the protein of interest, is returned to the first tank. The continuous extraction and filtration process is stopped when the protein concentration in the first tank is below 0.05 g / L and / or the final dilution factor is 40 (1:40).

[0170] The higher pH sample was obtained by resuspending the above precipitate in phosphate buffer (sodium hydrogen phosphate Na2HPO4 and sodium dihydrogen phosphate NaH2PO4) to obtain a first dilution factor of 5 (1:5) and a pH of 8.0. The suspension was stirred for 30 minutes at 20° C. All other conditions and procedures used in the higher pH sample were the same as for the low pH suspension (as described above), except for the pH value.

[0171] Tables 5 and 6 show the results after the suspension has been subjected to an ultrafiltration concentration step in a second filtration unit.

[0172] Table 5: IgG, IgA and IgM yields in the ultrafiltration concentration step

[0173]

[0174] The results confirmed that pH extraction conditions did not affect IgG, IgA or IgM yields. However, effects were observed on other parameters, such as low pH buffer conditions resulting in reduced levels of PKA and proteolytic activity in the preparation. Such parameters may have a negative impact on the stability / quality of immunoglobulin preparations. Parameters α1-antitrypsin, α2-macroglobulin, transferrin, albumin, Apo-AI, ceruloplasmin, haptoglobin, fibrinogen, fibronectin, hemopexin and IgG-subclass distribution were determined by immunoturbidimetry. Phospholipids, triglycerides and cholesterol levels were determined by enzymatic assays. Protein composition was performed by agarose gel electrophoresis. Molecular size distribution (aggregates, dimers, monomers and fragments) was determined by size exclusion chromatography. PKA and proteolytic activity were determined by chromogenic substrate assays.

[0175] Table 6: Impurity profile after ultrafiltration concentration step

[0176]

[0177] Example 4

[0178] In this example, the IgG recovery from the precipitate was compared by: i) dissolving the precipitate in a fixed volume of 220 mM sodium acetate (pH 4.8±0.2), resulting in a final dilution factor of 6 and recovering the solubilized protein by depth filtration; ii) dissolving the precipitate in 220 mM sodium acetate (pH 4.8±0.2) and recovering the solubilized protein to achieve a final dilution factor of 31 using a continuous extraction process of the present invention; and iii) using a continuous extraction process of the present invention, in which the suspension in the first tank is continuously replenished with fresh buffer to achieve a second dilution factor of 31.

[0179] Part i: Using the same impeller mixer (ID 10 cm), 1 kg of the same batch of precipitate was suspended in 5 kg of 220 mM sodium acetate (pH 4.8 ± 0.2) to obtain a final dilution factor of 6 (i.e. 1 kg of precipitate dissolved in 5 kg of buffer). The suspension was mixed for 8 hours. Before depth filtration, a filter aid (FA = 10 g / kg Celpure C100, Advanced World Mineral) was added and mixed for 30 min. Depth filtration was performed in a filter press (20x20 cm frame; from Filtrox) at a maximum pressure of 2.5 bar using a combination of filter papers (polypropylene from Dolder CH, cellulose, CH9 from Filtrox). The filtration area used was 3200 cm 2After the filtration was complete, a post-wash was started with 2.5 L of resuspension buffer. This resulted in a total filtrate of 6.9 L and a protein concentration of 18 g / L. The protein concentration was determined by Kjeldahl, Biuret and A280 assays. Finally, the filtrate was further concentrated to 20 g / L using an ultrafiltration membrane with an average molecular weight cutoff of 10 kD as described above. The final ultrafiltrate volume was 5.9 L with a protein concentration of 20.7 g / L (Table 7).

[0180] Part ii: A frozen protein-containing precipitate in the form of a precipitate containing about 100 g of filter aid from the Kistler-Nitschman method (KN) in an amount of 1 kg was resuspended in 220 mM sodium acetate (pH 4.8 ± 0.2) buffer for 30 min using an impeller mixer (ID 10 mm) to obtain a first dilution factor of 10 (i.e. 2 kg of precipitate dissolved in 18 kg of buffer). The suspension in the first tank (20 L working volume) was pumped into the first dynamic filtration treatment unit using a diaphragm pump at a flow rate of 1000 mL / min. The treatment unit comprises a double-layer ceramic-based membrane disk (upper membrane layer 80 nm and lower layer 100 nm). The ceramic filter disk 152 (KERAFOL Keramische Folien GmbH, 92676 Eschenbach) has a diameter of 152 mm; a thickness of 4.5 mm; and a thickness of 360 cm. 2 The tangential speed of the disk was about 7 m / s at 60 Hz (equivalent to 800 rpm). The average filtration rate was set to about 200 ml / min.

[0181] Once the first treatment unit is full, the suspension is circulated at a constant pressure of 1 bar (range: 0-2 bar) for 10-15 minutes using an overflow valve (which regulates the return of the first retentate from the first treatment unit to the first tank). At this point, the continuous extraction process begins, with the transmembrane pressure (TMP) maintained at 0.5-1.5 bar. The first permeate is collected in the second tank (20 L working volume) at a flow rate of 100-200 mL / min. The unfiltered retentate suspension flows back to the first tank through the regulated outlet valve at a flow rate of 800-900 mL / min. When a defined volume (2000-4800 mL) has been collected in the second tank (= filtrate tank), the extraction is started using a 0.2 m 2 , 10kD cutoff, / or Ultrafiltration (secondary filtration unit) of the filter (Milipore). The transmembrane pressure (TMP: 0.8-1.5 bar) was set so that the permeate flow rate of the UF system was similar to the permeate filtrate flow rate (100-200 mL / min) to ensure a continuous extraction process. The permeate of the UF-secondary filtration unit was returned to the first tank at a flow rate of 100-200 mL / min. After 4 hours, the filtration was stopped, with the predetermined value of the protein concentration in the first tank (suspension tank = feed tank) being below 0.1 g / L. This was equal to a final dilution ratio of 1:31. The ultrafiltration process was continued until the protein concentration reached 20 g / L. During this final concentration, the secondary permeate was sent to waste. The final ultrafiltrate volume was 7.3 L with a protein concentration of 21.4 g / L (Table 7). The protein concentration was determined by Kjeldahl assay.

[0182] Part III: In the third part of this experiment, the first filtration unit was used as a stand-alone system (i.e. disconnected from the second UF system). An amount of 1 kg of the same precipitate was resuspended in 5 kg to give a dilution factor of 6 (i.e. 1 kg of precipitate was dissolved in 5 kg of buffer), wherein the pH of the suspension was about 4.6-5.0. All other parameters of this experiment were the same as described in part ii), except that fresh buffer was added to the first tank instead of the permeate from the UF system. Once the first filtration unit was full, the suspension was recirculated at a constant pressure of 1 bar (range: 0-2 bar) for 10-15 minutes using an overflow return valve before starting the continuous extraction process. The filtrate was collected in the second tank (50 L working volume) at a flow rate of 100-200 mL / min. The unfiltered suspension was returned to the first tank at a flow rate of 800-900 mL / min through the regulated return valve. When a defined volume (2000-4800 mL) was collected in the second tank (=filtrate tank), fresh buffer was added to the suspension tank at a flow rate similar to the first permeate flow rate (i.e. 100-200 mL / min). After about 4 hours, the filtration was stopped, with a predetermined value of the protein concentration in the first tank (suspension tank=feed tank) being below 0.1 g / L. The volume of the collected filtrate was about 31 L with a protein concentration of 4.8 g / L. This volume was equivalent to a final dilution ratio of 1:31. The filtrate was further concentrated to a protein concentration of 20.6 g / L to give a final volume of 7.2 L (Table 7).

[0183] The results of IgG yield are shown in Table 7. The IgG yield according to the method of the present invention (which includes a continuous extraction and filtration process) gives a higher yield than the prior art method. As explained above, by using the extraction and filtration method as disclosed in the present invention, a concentration change by increasing the volume (or final dilution factor) is achieved, thereby changing the solubility equilibrium, which is beneficial to increase the extraction of immunoglobulin G to obtain a higher overall yield.

[0184] Table 7: Comparison of IgG yields between existing and new methods at different processing steps. (Initial dissolution time: is the mixing time before the sequential extraction and filtration units are started; PEQ stands for plasma equivalent, i.e. the amount of IgG from each liter of plasma).

[0185]

[0186] Examples: 5, 6 and 7

[0187] In these examples, the effect of the rotation speed of the spinning filter disc and the total recirculation volume (final dilution factor) in the first processing unit on the protein yield in the second tank was investigated. Table 8 provides a summary of the conditions used.

[0188] The results showed that the higher the rotation speed of the disk and the higher the recirculation volume, the higher the extracted target protein recovered in the second tank without increasing the co-extraction of unwanted impurities such as IgA, IgM, lipids and high molecular weight proteins.

[0189] Example 5A

[0190] For the experiment, Cohn I+II+III paste (1 kg, containing 120 grams of Celpure C100) was suspended in 10 mM sodium acetate and 10 mM sodium dihydrogen phosphate dihydrate, pH 4.3-4.4 buffer at a first dilution ratio of 1:6 in a first tank at 4°C. The suspension in the first tank was stirred with a paddle stirrer for about 15-20 hours at 4°C. Before starting the experiment, a first filtration unit (Novoflow dynamic filtration device, which comprises three ceramic filters with 0.2 μm membranes; filtration area = 0.1 m 2 ) was stored in cold water (1°C) overnight. At the beginning of the experiment, water was drained from the unit and the suspension was fed into the unit. The suspension was then recirculated between the first tank and the first treatment unit for a few minutes before the filtration process began. The remaining suspension was gradually added to the first treatment unit during the filtration process. The ceramic filter in the first treatment unit was operated at a speed of 1200 rpm and a TMP of 1.2 bar. The permeate from the first treatment unit was collected in the second tank and then fed to the second unit called the UF / DF unit. The UF / DF unit is a Novoflow dynamic filtration device, which contains 6 ceramic disks with a 7.0 nm membrane; filtration area 0.2 m 2The permeate flow rate of the UF / DF system is 50-70 mL / min. Once the first filtrate is collected in the second tank, the UF / DF system is started. The retentate of the UF / DF system flows back to the second tank, while the permeate flows back to the first tank. The permeate volume sent back to the first tank contributes to the total volume of liquid mixed with the paste (i.e., the final dilution factor). In this experiment, the total recirculation volume is 107 L / kg paste (i.e., a final dilution factor of 1:107).

[0191] Example 5B

[0192] In this example, the same procedure as described in Example 5A was used except that the total recycle volume was 16 L / kg paste.

[0193] Example 6A

[0194] In this example, the same procedure as described in Example 5A was used, except that the rotation speed of the ceramic filter in the first treatment unit was operated at 1000 rpm and the total recirculation volume was 102 L / kg paste.

[0195] Example 6B

[0196] In this example, the same procedure as described in Example 6A was used except that the total recycle volume was 16 L / kg paste.

[0197] Example 7A

[0198] In this example, the same procedure as described in Example 6A was used, except that the rotation speed of the ceramic filter in the first treatment unit was operated at 800 rpm and the total recirculation volume was 93 L / kg paste.

[0199] Example 7B

[0200] In this example, the same procedure as described in Example 7A was used except that the total recycle volume was 16 L / kg paste.

[0201] Table 8 provides the experimental parameters and target protein yield in the second tank after the filtration process.

[0202]

[0203] MgAl2O4=Magnesium Aluminum Oxide

[0204] * The protein yield was calculated relative to the starting suspension before the continuous filtration process began. The protein- and IgG yields in the suspension were set to 100%, (100% total protein in the suspension = 13.29 g protein / L plasma equivalent) and (100% total IgG in the suspension = 7.34 g IgG / L plasma equivalent)

[0205] Impurities were determined by turbidimetry, ELISA (IgA, IgM) or enzyme test methods (lipids). The results show that no significant increase in impurities was observed, but as Table 8 clearly shows, the protein yield as well as the IgG yield increased significantly with higher rotation speeds, and the protein and IgG yields were significantly higher when using a high final dilution factor (Examples 5A, 6A, 7A) compared to a low final dilution factor (Examples 5B, 6B, 7B).

[0206] Examples 8A and 8B

[0207] In this example, a dynamic cross-flow filtration process was compared in the presence (Example 8A) and absence (Example 8B) of a filter aid. The filter aid used was (Celpure C300; Advanced Minerals).

[0208] For the experiments, Cohn I+II+III paste (1.2 kg for Example 8A and 1.5 kg for Example 8B) was used. Each kg of paste contained 120 grams of filter aid. The paste was resuspended in 10 mM sodium acetate & 10 mM sodium dihydrogen phosphate dihydrate, pH 4.3-4.4 buffer at 4°C in an initial ratio of 1:6. The suspension was stirred with a paddle stirrer at 4°C for about 15-20 hours. Before starting the experiment, the first filtration unit (Novoflow dynamic filtration device, which contains three ceramic filters 0.2 μm membrane; filtration area = 0.1 m 2 ) was stored in cold water (1°C) overnight. At the beginning of the experiment, the water was drained and the suspension was fed into the dynamic filter device. The suspension was then recirculated between the first tank and the device for a few minutes before the filtration process began. The remaining suspension was gradually added during the filtration process (the ceramic filter was operated at 1200 rpm with a TMP of 1.2-1.6 bar). In each experiment, about 600 ml of buffer was exchanged 16-18 times. This corresponds to a buffer volume of about 9.6-10.8 L and is used to simulate the buffer recovery of the ultrafiltration / diafiltration unit during online operation. The filtrate was collected in an ice-cooled container under stirring (paddle stirrer) and the filtrate was stirred for another hour after the filtration was completed. Subsequently, the filtrate was stirred for 1 hour using a filtration machine. The filtrate was concentrated to 20 g / L (±5 g / L) using a Crossflow device.

[0209] In Example 8B, the filter aid was removed using a Mecaplex pressure filter sleeve and a polypropylene filter layer between the first tank and the first filter unit. All other conditions were the same as described in Example 8A.

[0210] Experiments have confirmed that the removal of the filter aid results in a higher filtration rate through the first filter unit ( Figure 2 ). In addition, the total protein and IgG recoveries in the filtrate were similar regardless of the presence or absence of filter aids. In addition, removing the filter aids before the first filtration unit also helps to remove lipids and other hydrophobic molecules present in the suspension from the filtrate (data not shown). Therefore, the filtrate obtained from the first filtration unit is more stable when operated in the absence of filter aids (i.e., the filtrate turbidity is relatively low and remains stable during storage compared to the filtrate obtained from the first filtration unit operated in the presence of filter aids). These results further indicate that removing the filter aids before the first filtration unit will increase the flux capacity of the system.

Claims

1. A method for extracting a protein of interest from a precipitate, the method comprising: a. mixing the precipitate with a liquid in a first tank (1) to form a suspension having a first dilution factor; b. feeding the suspension to a first filtration unit (5), the first filtration unit (5) comprising a dynamic filter element suitable for producing a first retentate and a first permeate enriched in the protein of interest; c. diluting the suspension in the first tank (1) by adding liquid to a second dilution factor, optionally by flowing the first retentate (13) into the first tank; and d. recovering the first permeate enriched in the protein of interest in a second tank (7), wherein Repeating steps b) to c) until the predetermined values ​​of the final dilution factor and protein concentration of the suspension in the first tank are reached; The predetermined value of the protein concentration is below 0.1 g / L.

2. A method for extracting a protein of interest from a precipitate, the method comprising: a. mixing the precipitate with a liquid in a first tank (1) to form a suspension having a first dilution factor; b. feeding the suspension to a first filtration unit (5), the first filtration unit (5) comprising a dynamic filter element suitable for producing a first retentate and a first permeate enriched in the protein of interest; c. diluting the suspension in the first tank (1) by adding liquid to a second dilution factor, optionally by flowing the first retentate (13) into the first tank; d. recovering the first permeate enriched in the protein of interest in a second tank (7); e. subjecting the first permeate in the second tank (7) to a continuous concentration process in a second filtration unit comprising a cross-flow filter element, thereby producing a second retentate enriched in the protein of interest and a second permeate depleted in the protein of interest; f. optionally diluting the suspension in the first tank (1) by passing a second permeate to the first tank (1), thereby diluting the suspension to a second dilution factor; as well as g. Returning the second retentate enriched in the protein of interest to the second tank (7) and / or collecting the second retentate enriched in the protein of interest.

3. An industrial-scale method for extracting a protein of interest from a precipitate with high yield, the method comprising: a. mixing the precipitate with a liquid in a first tank to form a suspension having a first dilution factor; b. continuously feeding the suspension into a first filtration unit, the first filtration unit comprising a rotating cross-flow filter element, the rotating cross-flow filter element comprising a filter disc having a ceramic membrane, the ceramic membrane having an average pore size of 5 nm-5000 nm, the filter element being suitable for producing a first retentate, and a first permeate enriched in the protein of interest; c. diluting the suspension in the first tank to a second dilution factor by adding liquid, in part, by flowing the first retentate into the first tank; d. recovering the first permeate enriched in the protein of interest in a second tank; and e. subjecting the first permeate in the second tank to a continuous concentration process in a second filtration unit comprising a cross-flow filter element, thereby producing a second retentate enriched in the protein of interest and a second permeate depleted in the protein of interest; f. optionally diluting the suspension in the first tank by continuously flowing the second permeate to the first tank, thereby diluting the suspension to a second dilution factor; as well as g. Returning the second retentate enriched in the protein of interest to the second tank and / or collecting the second retentate enriched in the protein of interest.

4. The method according to claim 2 or 3, wherein Repeating steps b) to c) or steps b) to f) until a predetermined value of the final dilution factor or protein concentration of the suspension in the first tank is reached; The predetermined value of the protein concentration is below 0.1 g / L.

5. The method according to claim 2 or 3, wherein The first permeate is fed continuously to the concentration process.

6. The method according to claim 2 or 3, wherein The concentration process is an ultrafiltration performed in a second filtration unit.

7. The method according to claim 2 or 3, wherein The first permeate is collected in a second tank and once the suspension in the first tank is completely filtered, the first permeate from the second tank is subjected to a continuous concentration process.

8. The method according to claim 2 or 3, wherein The first dilution factor is at least 3.

9. The method according to claim 4, wherein The final dilution factor was 6-70.

10. The method according to claim 2 or 3, wherein the precipitate is an intermediate product of an alcohol fractionation process.

11. The method according to claim 10, wherein The intermediate product is selected from Cohn fraction I (FrI), Cohn fraction II+III (FrII+III), Cohn fraction I+II+III (Fr I+II+III) or Kistler / Nitschmann precipitate A (KNA), or a combination of KNA with one or more of Fr I, Fr II+III and Fr I+II+III.

12. The method according to claim 2 or 3, wherein the precipitate is a culture supernatant or a fermentation product.

13. The method of claim 2 or 3, wherein the protein of interest is an immunoglobulin.

14. The method of claim 2 or 3, wherein the first filtration unit comprises a pressure vessel.

15. The method of claim 1 or 2, wherein the dynamic filter element is a dynamic cross-flow filter element.

16. The method according to claim 14, wherein The first filter unit is equipped with a rotating filter disc containing a ceramic membrane and optionally baffles for turbulent mixing of the contents of the first filter unit.

17. The method of claim 16, wherein the tangential speed of the disk is 1-7 m / sec.

18. The method according to claim 2 or 3, wherein the temperature in the first filtration unit is controlled to be 2°C-25°C.

19. The method according to claim 2 or 3, wherein the dynamic filter element or the cross-flow filter element comprises a filter membrane having an average pore size of 5 nm to 5000 nm.

20. The method of claim 2 or 3, wherein the precipitate comprises a filter aid.

21. The method of claim 20, wherein the filter aid is removed prior to the first filtration.

22. The method according to claim 2 or 3, wherein A second tank (7) is provided to receive the first permeate (14) and / or the second retentate (16), wherein the flow rates of the first permeate and the second permeate are controlled to maintain a substantially constant product volume in the second tank (7).

23. The method of claim 19, wherein the transmembrane pressure is 0.1 bar to 2.5 bar.

24. The method according to claim 2 or 3, wherein The extraction process is further assisted by adjusting the flow rate and / or the residence time of the suspension in the first filtration unit and / or the flow rate of the first retentate and / or the flow rate of the first permeate.

25. The method according to claim 2 or 3, wherein the pH of the suspension is 3.0-9.

0.

26. The method of claim 2 or 3, wherein the total protein concentration of the precipitate is 0.5-6.5% w / v.

27. The method according to claim 2 or 3, wherein The liquid comprises a buffer comprising one or more of sodium acetate, sodium phosphate and citric acid.

28. The method of claim 2 or 3, wherein the precipitate is added to the first tank in the form of a suspension, pellet or paste.

29. The method according to claim 2 or 3, wherein The product of the method is subjected to further processing, including one or more of a chromatography step, a viral inactivation step, concentration, and formulation, so that the final product is suitable for administration to a subject.

30. The method of claim 2 or 3, wherein the first dilution factor is 1-10.

31. The method of claim 2 or 3, wherein the first dilution factor is 3-9.

32. The method of claim 2 or 3, wherein the first dilution factor is 3-5.

33. The method of claim 2 or 3, wherein the first dilution factor is 3, 5, 6, 7, 9 or 10.

34. The method of claim 4, wherein the final dilution factor is 10-70.

35. The method of claim 4, wherein the final dilution factor is 20-50.

36. The method of claim 4, wherein the final dilution factor is 30-40.

37. The method of claim 4, wherein the final dilution factor is 10, 20, 30, 40, 50, 60 or 70.

38. The method according to claim 4, wherein the predetermined value of protein concentration is 0.001-0.1 g / L.

39. The method of claim 2 or 3, wherein the precipitate is an intermediate product of an alcohol fractionation process of plasma.

40. The method of claim 2 or 3, wherein the precipitate is an intermediate product of an alcohol fractionation process of human plasma.

41. The method of claim 2 or 3, wherein the protein of interest is immunoglobulin G.

42. The method of claim 2 or 3, wherein the protein of interest is immunoglobulin G from human plasma or recombinantly produced.

43. The method of claim 1 or 2, wherein the dynamic filter element is a rotating cross-flow filter element.

44. The method of claim 43, wherein the rotational speed of the rotating cross-flow filter element is 600 rpm to 1200 rpm.

45. The method of claim 43, wherein the rotational speed of the rotating cross-flow filter element is 800 rpm to 1200 rpm.

46. ​​The method of claim 43, wherein the rotation speed of the rotating cross-flow filter element is 800 rpm, 1000 rpm or 1200 rpm.

47. The method according to claim 2 or 3, wherein the temperature in the first filtration unit is controlled to be 2°C-10°C.

48. The method of claim 2 or 3, wherein The dynamic filter element or the cross-flow filter element comprises a filter membrane, and the average pore size of the filter membrane is 5nm-2000nm.

49. The method according to claim 2 or 3, wherein The dynamic filter element or the cross-flow filter element comprises a filter membrane, and the average pore size of the filter membrane is 5nm-500nm.

50. The method of claim 2 or 3, wherein The dynamic filter element or the cross-flow filter element comprises a filter membrane, and the average pore size of the filter membrane is 5nm-200nm.

51. The method of claim 2 or 3, wherein The dynamic filter element or the cross-flow filter element comprises a filter membrane, and the average pore size of the filter membrane is 7nm-100nm.

52. The method of claim 2 or 3, wherein The dynamic filter element or the cross-flow filter element comprises a filter membrane, and the average pore size of the filter membrane is 7nm-80nm.

53. The method of claim 19, wherein the transmembrane pressure is 0.2 bar to 2.4 bar.

54. The method of claim 19, wherein the transmembrane pressure is 0.4 bar to 2.0 bar.

55. The method of claim 19, wherein the transmembrane pressure is 0.4 bar to 1.5 bar.

56. The method of claim 2 or 3, wherein the pH of the suspension is 4.0-7.

0.

57. The method of claim 2 or 3, wherein the pH of the suspension is 4.0-6.

0.

58. The method of claim 2 or 3, wherein the pH of the suspension is 4.0-5.

0.

59. The method of claim 2 or 3, wherein the pH of the suspension is 4.3-4.

9.

60. The method of claim 2 or 3, wherein the pH of the suspension is 4.4-4.

8.

61. The method of claim 2 or 3, wherein the pH of the suspension is 5.

0.

62. The method of claim 2 or 3, wherein the total protein concentration of the precipitate is 1.0-4.0% w / v.

63. The method of claim 2 or 3, wherein the total protein concentration of the precipitate is 1.5-3.0% w / v.

64. The method of claim 2 or 3, wherein the total protein concentration of the precipitate is 1.8-2.5% w / v.

65. The method of claim 2 or 3, wherein the total protein concentration of the precipitate is 2.0% w / v.

Citation Information

Patent Citations

  • Methods of tangential flow filtration and an apparatus therefore

    US20040167320A1

  • Process for producing milk fractions rich in secretory immunoglobulins

    US20110130545A1

  • Process for isolating alpha1-antitrypsin from human or animal humors

    US3301842A

  • Improved process for the preparation of immunoglobulin g (IGG)

    WO2016012803A1

  • Method for preparing human serum albumin and globulin

    CN104086645A